ABT
NYSE · Health Care
Abbott Laboratories
$111.25
-0.02 (-0.02%)
Financial Highlights (FY 2026)
Revenue
43.92B
Net Income
6.46B
Gross Margin
56.7%
Profit Margin
14.7%
Rev Growth
+0.5%
D/E Ratio
0.25
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 56.7% | 56.7% | 52.0% | 52.0% |
| Operating Margin | 18.2% | 16.4% | 23.6% | 26.7% |
| Profit Margin | 14.7% | 14.0% | 18.1% | 16.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 43.92B | 43.70B | 33.22B | 38.26B |
| Gross Profit | 24.89B | 24.76B | 17.29B | 19.91B |
| Operating Income | 7.98B | 7.15B | 7.86B | 10.21B |
| Net Income | 6.46B | 5.79B | 6.02B | 6.40B |
| Gross Margin | 56.7% | 56.7% | 52.0% | 52.0% |
| Operating Margin | 18.2% | 16.4% | 23.6% | 26.7% |
| Profit Margin | 14.7% | 14.0% | 18.1% | 16.7% |
| Rev Growth | +0.5% | +0.5% | +10.5% | -2.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 19.15B | 19.15B | 25.40B | 31.10B |
| Total Equity | 77.20B | 77.20B | 104.22B | 116.10B |
| D/E Ratio | 0.25 | 0.25 | 0.24 | 0.27 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 9.65B | 9.12B | 10.39B | 11.25B |
| Free Cash Flow | — | — | 6.26B | 6.35B |